| P50 | author | M J Calasanz | Q67566883 |
| P2093 | author name string | Gemma Azaceta | |
| | Luis Palomera | |
| | Isabel Izquierdo | |
| | Victoria Dourdil | |
| | Elena Bonafonte | |
| P2860 | cites work | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 |
| | The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes | Q35848032 |
| | JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones | Q43264134 |
| | JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis | Q46827275 |
| | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. | Q51618906 |
| | JAK2 V617F mutation is associated with 5q- syndrome in Chinese. | Q54735977 |
| | Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia | Q58865927 |
| | The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow | Q58865932 |
| | High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable | Q79631497 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chromosomal deletion syndrome | Q16918398 |
| | myelodysplastic syndrome | Q954625 |
| P304 | page(s) | 1941-1943 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation | |
| P478 | volume | 51 | |